Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up
- 1 March 2016
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 58, 41-51
- https://doi.org/10.1016/j.ejca.2016.01.009
Abstract
No abstract availableKeywords
Funding Information
- Covidien
- ITG
- Eckart
- Ziegler
- MSD Nordion
This publication has 19 references indexed in Scilit:
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Role of PET/CT in the functional imaging of endocrine pancreatic tumorsAbdominal Radiology, 2012
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumoursEndocrine-Related Cancer, 2011
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Gastroenteropancreatic (neuro)endocrine neoplasms: The histology reportDigestive and Liver Disease, 2011
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideJournal of Clinical Oncology, 2010
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and SurvivalJournal of Clinical Oncology, 2008
- Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004